27 articles for BK Trivedi
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Second generation"peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile.
Warner-Lambert
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.
Warner-Lambert
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bond.
Warner-Lambert
Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents.
Warner-Lambert
N6-substituted adenosine receptor agonists: potential antihypertensive agents.
Warner-Lambert
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
Warner-Lambert
N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor.
Warner-Lambert
N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
Warner-Lambert
N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
Warner-Lambert
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
Parke-Davis Pharmaceutical Research Division
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.
Pfizer
A series of conformationally and sterically constrained analogs of N-phenyl-N′-aralkylurea ACAT inhibitors
TBA
Substituted N,N′-diphenyl ureas as potent inhibitors of acyl-CoA:Cholesterol acyltransferase (ACAT)
TBA
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Pfizer
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Pfizer
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Pfizer
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Pfizer
Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Pfizer
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
Parke-Davis Pharmaceutical Research
Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel beta-ketoamides as hypocholesterolemic agents.
Warner-Lambert
Inhibitors of acyl-Coa:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents.
Warner-Lambert
[1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.
Warner-Lambert
